Moderna norovirus vaccine trial on hold by US FDA over neurological side effect
Moderna said on Friday that the U.S. FDA paused a late-stage trial of its experimental norovirus vaccine after a case of a ...
Healio12h
FDA sets date for decision on twice-yearly shots to prevent HIV
The FDA has accepted Gilead Sciences’ new drug application for lenacapavir as a long-lasting injectable to prevent HIV ...
MarketWatch4d
Moderna Swings to 4Q Loss After Early Launch of Updated Vaccine
Moderna swung to a loss in the last three months of the year after an early launch of its updated Covid-19 vaccine shifted sales out of the fourth quarter. The maker of the Spikevax Covid-19 ...
Nasdaq27d
After a Reset Year, Is Moderna Stock Poised for a Comeback?
Biotechnology company Moderna Inc. (NASDAQ ... to treat infectious diseases like RSV, Zika, and HIV, as well as help create cancer vaccines. However, the company has struggled to diversify ...
Yahoo Finance25d
Moderna Awarded Tender for the Supply of Its mRNA COVID-19 Vaccine in the European Union
Under the resulting agreement, 17 participating countries can access Moderna's mRNA COVID-19 vaccine for up to four years. "This agreement presents an opportunity for Moderna to support and ...
AOL5d
As bird flu becomes a growing threat, Moderna is awarded $590M to develop mRNA pandemic influenza vaccines
To that end, HHS has granted Moderna $590 million to help accelerate the development of a bird flu vaccine. The agency announced its backing of the Massachusetts-based pharmaceutical firm about 72 ...
FiercePharma4d
Moderna shoulders $238M contract manufacturing cancellation charge in Q4
Among the handful of drugmakers to advance a successful COVID-19 vaccine in 2020, Moderna—whose mRNA shot Spikevax was also ...
Moderna outlines $1.5B-$2.5B 2025 revenue target with focus on 10 product approvals
Q4 2024 Management View Moderna CEO Stéphane Bancel highlighted 2024 as a year of significant progress, with revenues reaching $3.2 billion. The company reduced operating expenses by $2.6 billion and ...